CCRC - Certified Clinical Research Coordinator Investigational Product Management Questions and Answers — Questions and Answers
Question 1: Which of the following elements is essential for a compliant Investigational Product (IP) accountability record at a clinical trial site?
- Lot number, expiration date, and quantities received, dispensed, and returned. (Correct answer)
- The participant's full name and medical record number for each dispensing event.
- The name and signature of the monitor who last reviewed the records.
- The manufacturing cost and batch release date of the investigational product.
Correct answer: Lot number, expiration date, and quantities received, dispensed, and returned.
ICH GCP guidelines require meticulous tracking of the IP to ensure it's only used for study participants as per the protocol. The accountability record, or drug accountability log, must track the lifecycle of the IP at the site, which includes unique identifiers like lot/batch numbers and expiration dates, as well as a running inventory of units received from the sponsor, dispensed to each participant (identified by a unique subject ID), and returned or otherwise disposed of.
Question 2: In a double-blind study, a participant experiences a severe adverse event requiring hospitalization. The emergency room physician believes knowing the treatment assignment is critical for patient management. What is the CRC's most appropriate initial action?
- Immediately access the unblinding envelope and inform the physician of the treatment assignment.
- Contact the Principal Investigator (PI) immediately and follow the protocol-specific procedure for emergency unblinding. (Correct answer)
- Instruct the physician to treat the symptoms without unblinding to protect the integrity of the study.
- Tell the physician to call the sponsor's general hotline to request the unblinding information directly.
Correct answer: Contact the Principal Investigator (PI) immediately and follow the protocol-specific procedure for emergency unblinding.
Patient safety is paramount, but unblinding must follow a pre-defined process to protect study integrity as much as possible. The protocol will specify the exact steps for emergency unblinding. The CRC's role is to immediately involve the PI, who is medically responsible, and initiate the formal procedure. The PI must be able to unblind a participant independently in a medical emergency without delay or requiring permission from the sponsor.
Question 3: A participant returns a partially used bottle of an oral investigational drug at a routine study visit. According to good clinical practice, what is the CRC's primary responsibility regarding the returned product?
- Instruct the participant to take the remaining product home for proper disposal.
- Immediately dispose of the unused product in a standard biohazard container.
- Accurately count the returned units, document the quantity on the accountability log, and store it securely per sponsor/protocol instructions. (Correct answer)
- Offer the unused product to another participant who may have lost their supply to prevent waste.
Correct answer: Accurately count the returned units, document the quantity on the accountability log, and store it securely per sponsor/protocol instructions.
The site must maintain complete accountability for the investigational product from receipt to final disposition. This includes documenting the exact quantity of product returned by the participant and storing it securely. This process is crucial for assessing compliance and ensuring a complete reconciliation of all IP units at the end of the study, which are then either returned to the sponsor or destroyed according to the sponsor's specific written instructions.
Question 4: According to U.S. federal regulations (21 CFR 312.6), which of the following statements is a mandatory element for the label of an investigational new drug?
- The name of the Principal Investigator and the site number.
- "Caution: New Drug—Limited by Federal (or United States) law to investigational use." (Correct answer)
- The date the protocol was approved by the Institutional Review Board (IRB).
- A full list of all potential adverse reactions listed in the Investigator's Brochure.
Correct answer: "Caution: New Drug—Limited by Federal (or United States) law to investigational use."
Federal regulation 21 CFR 312.6(a) explicitly mandates that the immediate package of an investigational new drug must bear the statement: "Caution: New Drug—Limited by Federal (or United States) law to investigational use." This is a critical regulatory requirement to clearly identify the product's status and restrict its use to the context of a clinical trial.
Question 5: A CRC receives a shipment of investigational product. Upon inspection, the CRC notes that the external shipping container is intact, but the seal on one of the primary drug bottles inside is broken. What is the most appropriate action?
- Document the broken seal on the shipping receipt and store the affected bottle with the general IP inventory.
- Use the product from the bottle since the outer container was sealed, assuming it was a minor manufacturing defect.
- Segregate the bottle with the broken seal, quarantine it, document the issue thoroughly, and contact the sponsor/depot for instructions. (Correct answer)
- Discard the bottle immediately in the pharmaceutical waste and only document the receipt of the intact bottles to avoid confusion.
Correct answer: Segregate the bottle with the broken seal, quarantine it, document the issue thoroughly, and contact the sponsor/depot for instructions.
The integrity of the investigational product is paramount to patient safety and data validity. A broken seal compromises the product's integrity. The correct procedure is to immediately isolate the affected product to prevent it from being dispensed, document the deviation clearly on all records, and quarantine it while contacting the sponsor or designated pharmacy/depot for guidance on how to handle the compromised unit (e.g., return or destruction).
Question 6: A CRC is preparing to dispense an investigational drug to a study participant for the first time. Which of the following is a critical prerequisite before any drug can be dispensed to that specific participant?
- Ensuring the participant has scheduled their next three study visits.
- Verifying that the site has received payment from the sponsor for the participant's screening visit.
- Confirming that a valid, signed informed consent form for the participant is on file and the PI has authorized the prescription/order. (Correct answer)
- Updating the electronic Case Report Form (eCRF) with the anticipated dispensing date.
Correct answer: Confirming that a valid, signed informed consent form for the participant is on file and the PI has authorized the prescription/order.
Before any study procedures, including the dispensing of an investigational drug, can occur, the participant must have voluntarily given informed consent, which must be documented via a signed and dated consent form. Furthermore, the dispensing of the drug, like any prescription, must be done upon the order of the Principal Investigator or another authorized prescriber as delegated. The pharmacy or person dispensing must verify these elements are in place before releasing the IP.
CCRC - Certified Clinical Research Coordinator Investigational Product Management Questions and Answers
Which of the following elements is essential for a compliant Investigational Product (IP) accountability record at a clinical trial site?